Mashup Score:13
VJHemOncTreating Richter’s transformation with venetoclax, obinutuzumab and atezolizumab - 5 days
Mashup Score:13
Twitter Feed: VJHemOnc
Mashup Score:7
VJHemOncPost-ASH 2021 International Workshop on Acute Leukemias (iwAL) Virtual Workshop - 3 days
Mashup Score:7
Apply to register for the Post-ASH 2021 iwAL Virtual Workshop, featuring key abstracts in ALL, MDS & AML presented...
-
The post-ASH iwAL Virtual Workshop starts tomorrow! Featuring presentations & discussions on selected abstracts in ALL, AML & MDS from the 63rd ASH Annual Meeting Yet to register? Apply here: https://t.co/51999l2tmC #LeuSM #HemeOnc #ALLsm #AMLsm #MDSsm #iwAL https://t.co/51999l2tmC - view on twitter
Mashup Score:6
VJHemOncMASTER: Dara-KRd in patients with multiple myeloma - 4 days
Mashup Score:6
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507),...
-
💥MRD–based response-adapted therapy💥 Luciano Costa (@End_myeloma) of @uabmedicine comments on the results of MASTER: Dara-KRd in patients with #MultipleMyeloma Hear more: https://t.co/VxGMXazdCU #ASH21 @ASH_hematology #HemOnc #MMsm #Myeloma #TrialUpdate #CTSM #mmMRD - view on twitter
Mashup Score:6
VJHemOncStratifying patients receiving CAR-T cell therapy with CAR-HEMATOTOX - 1 week
Mashup Score:6
Kai Rejeski, MD, LMU Hospital Munich, Munich, Germany, discusses the use of the CAR-HEMATOTOX score to identify patients who...
-
@VJHemOnc caught up w/ @KRejeski of @LMU_Muenchen on the use of the CAR-HEMATOTOX score to identify patients who are at risk of non-relapse mortality post #CART Hear more on the team’s interesting findings: https://t.co/A9CPT0DpfN #ASH21 @ASH_hematology #HemOnc #ImmunoOnc - view on twitter
Mashup Score:4
VJHemOncOral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up - 1 day
Mashup Score:4
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, presents the latest findings from the Phase III...
-
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up w/ Andrew Wei (@AlfredHealth): https://t.co/B2cWYUI3FV #ASH21 @ASH_hematology #HemOnc #Leukemia #LeuSM #AMLsm #CTSM #TrialUpdate - view on twitter
Mashup Score:4
VJHemOncPOLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCL - 1 week
Mashup Score:4
John Burke, MD, Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, presents findings from the Phase III POLARIX...
-
POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in #DLBCL John Burke shares the trial details: https://t.co/9bmmKU18da #ASH21 @ASH_hematology #HemOnc #Lymphoma #LymSM #TrialUpdate #ImmunoOnc #CTSM - view on twitter
Mashup Score:4
VJHemOncTreating patients with poor-risk cytogenetics with venetoclax and HMAs - 19 hours
Mashup Score:4
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses outcomes of treatment-naïve patients with acute myeloid leukemia (AML)...
-
👉Treating patients with #AML with poor-risk cytogenetics with venetoclax and HMAs👈 @DanPollyea (@CUDenver) comments on data from an analysis of 2 recent clinical trials: https://t.co/Fcz5N6E6mZ #ASH21 @ASH_hematology #HemOnc #Leukemia #LeuSM #AMLsm - view on twitter
Mashup Score:3
register.gotowebinar.comRegistration - 1 day
Mashup Score:3
...
-
The @VJHemOnc post-ASH #Lymphoma Session, w/ Graham Collins & Wendy Osborne Don’t miss an expert discussion on the highlights from #ASH21 and their impact on clinical practice 🩺 Register now 💥https://t.co/0wYIiC9Em2💥 #Lymsm #HemOnc #VJSession https://t.co/0wYIiC9Em2💥 - view on twitter
Mashup Score:3
register.gotowebinar.comRegistration - 3 days
Mashup Score:3
...
-
🔊Post-ASH #Lymphoma Session with @VJHemOnc! Join UK experts @graham74GC & Wendy Osborne to hear key highlights from #ASH21 📅Feb 1st | 18.00 GMT / 13.00 EST / 10.00 PST Register now 💥https://t.co/0wYIiC9Em2💥 #Lymsm #HemOnc #VJSessions https://t.co/0wYIiC9Em2💥 - view on twitter
Mashup Score:3
VJHemOncHOVON 141/VISION: MRD guided time-limited treatment in CLL - 6 days
Mashup Score:3
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents results from the prospective, randomized Phase II HOVON-141/VISION trial...
-
HOVON 141/VISION: MRD guided time-limited treatment in CLL Carsten Niemann (@uni_copenhagen) shares the results of the Phase II trial assessing time-limited venetoclax & ibrutinib for R/R #CLL: https://t.co/9PZDZOtE8r #ASH21 #HemOnc #Leukemia #LeuSM #CLLsm #CTSM #TrialUpdate - view on twitter
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase II...
Treating Richter’s transformation with venetoclax, obinutuzumab & atezolizumab ⭐Promising preliminary data with all patients achieving remission after treatment Hear from @NitinJainMD (@MDAndersonNews): https://t.co/vWMP1Xtj5n #ASH21 #HemOnc #Leukemia #LeuSM #CLLsm #ImmunoOnc - view on twitter